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Background: Our previous studies indicated that oxidative stress up-regulated the expression of β-amyloid
precursor protein cleavage enzyme-1 (BACE1) in rat retina. Pharmacological reports have shown Timosaponin-BII, a
purified extract originating from Chinese medical herb Rhizoma Anemarrhenae, is characterized as an antioxidant.
Our present study aimed to determine whether Timosaponin-BII affected the expression of BACE1, β-amyloid
precursor protein cleavage production of Aβ1-40 and β-C-terminal fragment (β-CTF) in rat retina, which were
pre-treated with the oxidizing agent (solution of FeCl3).
Results: Few distinctions of BACE1 distribution were observed among all groups (normal control group, model
group, Timosaponin-BII treated and vehicle control groups). Rat retinas in model group and vehicle control group
manifested an apparent up-regulation of BACE1 expression. Meanwhile, the level of malonaldehyde (MDA), Aβ1-40
and β-CTF were increased. However, when comparing with the vehicle control group, the retinas in
Timosaponin-BII treated group showed significantly less BACE1 (p<0.05) and accumulated less Aβ1-40 or β-CTF
(p<0.05). It also showed significantly decreased level of MDA (p<0.05) and prolonged partial thromboplastin time
(p<0.05).
Conclusion: Our data suggested that Timosaponin-BII remarkably inhibited the up-regulation of BACE1 and
reduced the over-production of β-CTF and Aβ in rat retina, which was induced by FeCl3. The mechanism of
Timosaponin-BII on BACE1 expression may be related to its antioxidant property.
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Alzheimer’s disease (AD) is a progressive neurodegen-
erative disease prevalent in aged populations and charac-
terized by the presence of senile plaques (SP),
neurofibrillary tangles (NTFs), capillary cerebral amyloid
angiopathy (capCAA) and the abnormal loss of synapses
[1,2]. The amyloid deposition, whose disposal mechan-
isms have attracted great attention to neurologists, is
regarded as a main etiology. It has been documented
that accumulation of amyloid β-peptide (Aβ), which is a
cleavage form of β-site amyloid precursor protein (β-
APP), acts as a fundamental initiator of this disease [3].
β-APP is cleaved by β-amyloid precursor protein cleav-
age enzyme-1 (BACE1), along with the digestion by γ-* Correspondence: xiongkun2001@163.com
1Department of Anatomy and Neurobiology, School of Basic Medical
Sciences, Central South University, Changsha, Hunan 410013, China
Full list of author information is available at the end of the article
© 2012 Huang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsecretase, which results in the release of Aβ [4]. There-
fore, BACE1 plays a significant role in secretion of Aβ.
Previous studies have shown that different pathological
conditions, including traumatic brain injury, cerebral
ischemia, oxidative stress, functional deprivation, lead
exposure, ischemia and hypoxia, contribute to the up-
regulation of BACE1 expression or facilitate its activity,
and eventually lead to the massive accumulation of Aβ
[5-11]. Our previous data showed that oxidative stress
induced by the intra-vitreous injection of FeCl3 solution
elevated the expression of BACE1 in rats’ retina, and
consequently triggered the dramatic production of Aβ
[12]. This finding is in agreement with other studies [13-
15]. It is generally accepted that up-regulation of BACE1
expression as well as the degree of activated BACE1 is
closely related to the aggravation and the onset of AD
[16,17]. Therefore, investigations focused on inhibiting
either excessive generation or hyperactivity of BACE1Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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symptoms or even eradicating of the disease in early
stage.
Zhimu, a traditional Chinese medicine, is derived from
the dry rhizome of the plant Anemarrhena asphodeloides
Bge, Numerous steroids have been extracted from this
plant, such as sarsasapogenin, markosapogenin, negito-
genin, and their glycosylated products named Timosaponin-
AI, -AII, -AIII, -AIV, -BI and -BII [18]. It has been
reported that Timosaponin-BII has a neuronal protective
and anti-inflammatory effect possibly by suppressing
the production of pro-inflammatory factors IL-1, IL-6
and TNF-α [19-21]. The dementia-palliative effect of
Timosaponin-BII may involve multiple mechanisms
and one of them is its potential anti-oxidative property.
An intriguing observation from Ouyang’s experiment
showed that Timosaponin-BII diminished the Aβ-
induced oxidative impairment by promoting scavenging
of superoxide radicals [22]. Nevertheless, it is to be elu-
cidated whether this neuronal protective effect would in-
hibit the oxidant-induced up-regulation of BACE1
expression and even would attenuate the overproduction
of Aβ with its anti-oxidant property. In the present
study, we constructed an oxidative impairment animal
model by intra-vitreous injection of FeCl3 solutions then
administered Timosaponin-BII to these animal models.
The current study aimed to determine whether
Timosaponin-BII could inhibit the production of BACE1
in the retina including Aβ and malondialdehyde (MDA),




The powder of Timosaponin-BII was provided by Pro-
fessor Wan-Sheng Chen from Department of Pharma-
cology, School of Pharmacology, Second Military
Medical University, Shanghai, China [23] and its purity
is above 98%. Timosaponin-BII was dissolved in normal
saline (NS) at 1.2 g/ml in room temperature (24°C), sub-
sequently diluted FeCl3 (Sigma, MO, USA) with 0.01M
PBS at 10 mM to yield a low concentration working
solutions. The working concentration to induce the
proper increase of BACE1 expression and Aβ aggrega-
tion has been determined in our previous study [12].
Animals
Twenty-four adult male SD rats weighing 200–250 g
and aged 2–3 months were purchased from Animal
Center of Xiangya School of Medicine, Central South
University. All rats were isocoria with eyes observed
transparent and no deformity. The laboratory animals
were housed in a constant temperature at 24°C with
relative humidity at (55±10) %. All experiments werecarried out according to the principles outlined in the
NIH Guide for Care and Use of Laboratory Animals.
The present study was approved by Animal Ethics Com-
mittee of Xiangya School of Medicine, Central South
University.
Animal model construction and drug administration
Rats were equally divided into four groups randomly:
The normal control group (CTL), the model group
(FeCl3), the vehicle control group (FeCl3+NS) and the
experimental group (FeCl3+Timosaponin-BII). The
methods of constructing models were previously
described in detail in our paper [12], and briefly
described as follows: We anaesthetized the rats with
chloral hydrate by peritoneal injection and fixed them at
stereotaxic apparatus with eyes properly exposed. After-
wards, we extracted equal amount of humor vitreous
and injected the FeCl3 solution at 5 μl with a needle
penetrating the eyeball from the dorsal sclera at 1 mm
posterior to the cornea–sclera junction and toward the
center of the eye for 2 mm deep. The procedure was
cautiously carried out to avoid penetrating the beyond
lens. The experimental group received Timosaponin-BII
at 6 mg/kg by intravenous injection every morning for
14 days [24] while the vehicle control group was given
an injection of equal amount of normal saline. No drugs
were administered to the normal control or model
group. At the 14th day, we randomly selected three in
each group for morphological studies while the
remaining animals were used for biochemistry studies.
Prothrombin time assay
Blood samplings were collected by puncturing the heart
using natrium citricum negative pressure tubes that was
provided by Department of Laboratory, the Third Xian-
gya Hospital of Central South University. The rats were
deeply anaesthetized with chloral hydrate and their
chests were promptly opened in order to expose the
heart. Consequently we punctured the left artrium with
a negative pressure tube. Three milliliters of blood sam-
ples were collected from the experimental group and the
vehicle control group for the determination of Pro-
thrombin time (PT), Activated partial thromboplastin
time (APTT), Thrombin time (TT) and the concentra-
tion of Fibrinogen (FIB). Subsequently, the rats were
transcardiacally perfused.
Immunofluorescence staining
The eyeballs were removed following trans-cardiac per-
fusion with 4% paraformaldehyde in PBS at certain sur-
vival time point, post-fixed in the perfusion solution
overnight, followed by cryo-protection in 30% sucrose.
The eyeballs were cut in a cryostat at 14 μm thickness.
Cross-retinal sections near and passing the optic nerve
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(VWR, PA, USA).
Sections were incubated overnight at 4°C either with
BACE1 antibody (1:200; polyclone, AB5940, Millipore,
MA, USA) after blocked by PBS solution containing 10%
BSA and 0.3% Triton X-100 (Sigma, MO, USA) for 1 hr.
Immunoreaction products were visualized following 2 hr
incubation with Alexa FluorW 568 conjugated donkey
anti-rabbit IgG (1:200; Invitrogen, CA, USA). Sections
were counterstained with Hoechst 33342 (1:50k; Sigma,
MO, USA), washed, and mounted with anti-fading
medium before microscopic examination. Digital images
were obtained using fluorescence microscopy (Olympus,
BH-40, Tokyo, Japan).
Western blotting
For biochemical studies, the eyeballs were removed fol-
lowing a vascular rinse with ice cold PBS under overdose
anesthesia (sodium pentobarbital 100 mg/kg, i.p.) in
each group. The retinas were dissected out in cold PBS
on ice, carefully soaked with a piece of filter paper, then
collected in 1.5 ml test tubes and weighed. The retinas
were homogenized by sonication in cell lysis buffer (10×
w/v, Pierce Inc., CA, USA) containing a cocktail of pro-
tease inhibitors (Roche, IN, USA). Tissue lysates were
centrifuged (Ependoff, CA, USA) at 15,000×g at 4°C for
15 min after standing on ice for 1 hr. Supernatants were
collected and protein concentrations were determined
by BCA protein assay (Pierce Inc., CA, USA). Equal
quantity of protein (40–100 μg depending on target pro-
teins) was run on 10% SDS-PAGE gel (Bio-Rad, CA,
USA) after protein denaturation. The polypeptides were
electro-transferred to Trans-BlotW pure nitrocellulose
membrane (Bio-Rad, CA, USA). Non-specific binding
was blocked with PBS containing 5% non-fat milk.
Nitrocellulose membranes were incubated with primary
antibodies to BACE1, APP (1:500; polyclone, AHP538,
Serotec, CA, USA) and β-tubulin (1:10k; polyclone,
Sigma, MO, USA) overnight in 4°C. Membranes were
further incubated in HRP-conjugated secondary anti-
bodies (1:20k; Bio-Rad, CA, USA) for 1 hr. Protein
bands were visualized with an ECL PlusTM Western Blot-
ting Detection kit according to manufacturer’s instruc-
tion (GE Healthcare Life Sci., NJ, USA).
Aβ1-40 ELISA Assay
Aβ 1–40 levels in retina extracts were assayed using a
commercial kit according to manufacturer’s instruction
(Biosource International, CA, USA), except that the re-
porter antibody supplied by the manufacturer was
replaced with biotinylated 4G8 at 1:4k (Signet Laborator-
ies Inc., MA, USA). Equal quantity (80 μg) of protein
was loaded in each well and each analysis performed in
duplicate.MDA concentration assay
MDA levels in retina extracts were assayed using a com-
mercial kit according to manufacturer’s instruction
(Jian-Cheng Biotechnical Co., Nanjing, China), the
standard reference substance named tetraethoxypropane
were used in 10 nmol/ml. Equal quantity (100 μg) of
protein was loaded in each well and each analysis per-
formed in duplicate.
Statistic analysis
Specific density was calculated by subtracting back-
ground density on the membrane from total density
measured over the protein band, followed by
standardization to β-tubulin references using the soft-
ware of Image J (Image J, MD, USA). For ELISA data,
levels of Aβ1-40 were determined by a standard curve
generated using serially diluted synthetic Aβ1-40 peptide
provided in the kit. Finally, all data were normalized to
the means of inner reference (for western blotting) or
the means of control group (for ELISA data) whenever
appropriate, yielding relative values expressed as percen-
tages of controls (control serve as 100%).
Statistical analyze of normalized values were con-
ducted using one-way ANOVA followed by PASW SPSS
19.0 (SPSS, CA, USA), yielding p values between individ-
ual groups. The data expressed as means±SD. The min-
imal significant level of difference between groups was
set at p<0.05.
Digital images of retinal immunolabeling were cap-
tured at 40× objectives at comparable retinal segments
(~0.5 mm apart from the optic head). All illustrations
were prepared with Adobe Photoshop CS 6.0 (Adobe,
CA, USA). Whole panel images were converted to TIFF




When compared with the vehicle control, Timosaponin-
BII treated rats had no difference in TT, PT and the
concentration of FIB while the APTT was significantly
longer (Figure 1). This result indicated that
Timosaponin-BII had an inhibitory effect on intrinsic
coagulation system, which is in agreement with a previ-
ous study of Lu et al. (2011) [24].
Timosaponin-BII decreased BACE-1 expression in rat
retina
The immunofluorescence staining result showed that
BACE1 was mainly present in inner plexiform layer (IPL),
outer plexiform layer (OPL) and the nerve fiber layer
(NFL). Slight cellular dispersion also existed in the inner
and out nuclear layers. These results were consistent with
our previous studies [12]. In contrast with the normal
Figure 1 Effect of Timosaponin-BII on Prothrombin time (PT).
Activated partial thromboplastin time (APTT), Thrombin time (TT)
and the concentration of Fibrinogen (FIB). *: compared with vehicle
control group: p<0.05, n=3.
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cantly more distinct and heavier BACE1 immunoreactivity
and exhibited no apparent discrepancies in the cellular and
laminar distribution of BACE1. The vehicle control showed
a similar expression pattern as the model group. AlthoughFigure 2 Immunofluorescence staining of BACE1 in rat retina. A-D illu
model group (B), vehicle control group (C) and experimental group (D). E-H
vehicle control group (F) and experimental group (H). Scale bar =100 μm ino difference in distribution was detected, the experimen-
tal group displayed remarkably lower immunoreactivity
when compared with the model group and the vehicle con-
trol, but it remained higher than the normal control
(Figure 2).
The western blotting results showed that BACE1 was
mainly exhibited as a single 46 kDa band in all groups.
The bands in model group as well as in the vehicle con-
trol group were apparently thicker and larger than those
of normal control group. The band in the experimental
group was thinner and smaller than those in model
group and vehicle control but remained larger than the
normal ones (Figure 3A).
Timosaponin-BII decreased the overproduction of β-CTF
in rat retina
β-CTF (BACE1 cleavage product) and β-tubulin were
mainly exhibited as a single 14 kDa band or 55 kDa
band respectively in all the four groups. The bands of β-
CTF in model group as well as the vehicle control groupstrated the laminar-specific BACE1 expression in normal group (A),
illustrated Hoechst staining in normal rat (E), model group (F),
n H applied to all panels.
Figure 3 Western blotting analysis result of BACE1 and β-CTF. A: bands of BACE1, β-CTF and β-tubulin; B: optical density analysis of BACE1;
C: optical density analysis of β-CTF. *: compared with normal control group: p<0.05; #: compared with vehicle control group: p>0.05; Δ: compared
with normal control group: p<0.05; **: compared with model groups or vehicle control group: p<0.05, n=3.
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The bands in the experimental group were thinner and
smaller than those in model group and vehicle control
but remained larger than the normal ones (Figure 3A).
The optical density measurement and statistical ana-
lysis indicated that the vitreous injection of FeCl3 up-
regulated the expression of BACE1 and resulted in the
overproduction of β-CTF. The vehicle control group
showed a similar result with the model group. The rats
that were administered with Timosaponin-BII apparently
manifested a significant decrease in BACE1 expression
and β-CTF production in relation to the model group
and the vehicle control groups but still remained higher
than the normal ones (Figure 3B, C).Figure 4 Statistic analysis of Aβ1-40 level in rat retina in
relation to the normal control. *: compared with normal
control group: p<0.05; △: compared with model groups: p>0.05; #:
compared with model group or vehicle control group: p<0.05, n=3,
control serve as 100%.Timosaponin-BII inhibited overproduction of Aβ in rat
retina
The statistics analysis of ELISA result for Aβ1-40 level
was described in Figure 4. No discrepancies in Aβ1-40
concentration were observed between the model group
and the vehicle control group but both the two groups
showed the upsurge in relation to the normal control
group. The level of Aβ1-40 in Timosaponin-BII treated
group was lower than those in model group and ve-
hicle group but remained higher than those in the normal
control group. This result indicated that Timosaponin-
BII remarkably inhibited overproduction of Aβ that was
induced by up-regulation of BACE1. Nevertheless, the
effect of Timosaponin-BII was limited in extent sincethe level of target peptides was still higher than those in
normal condition.
Timosaponin-BII reduced MDA production in rat retina
The statistics analysis of MDA level is shown in Figure 5.
No discrepancies in MDA concentration were observed
between the model group and the vehicle control group
but both groups showed the upsurge in relation to the
normal control group. The level of MDA in the experi-
mental group was lower than those in model group and
vehicle control group but remained higher than those in
the normal control group. This result indicated that
Figure 5 Statistical analysis of MDA level in rat retina.
*: compared with normal control group: p<0.05; #: compared with
vehicle control group: p>0.05; △: compared with normal control
group: p<0.05; **: compared with model group or experimental
group: p<0.05. n=3.
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induced by the FeCl3 in rats’ retina. Nonetheless, the
capacity was limited as the oxidative stress remained
higher in the normal control group.
Discussion
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disease, which is characterized as deterioration of
memory and global cognitive ability, in addition to the
impairment of language skills and the extreme apathy
and exhaustion [25,26]. Senile plaques, neurofibrillary
tangles, capillary cerebral amyloid angiopathy and the
abnormal loss of synapses are proposed to be the princi-
pal pathological changes in AD [1,2]. Moreover, the
amyloid plaque originating from the β-APP abnormal
proteolysis product Aβ is considered to be the predom-
inant feature of the disease. In addition to the frontal
lobe, occipital lobe and the hippocampus that were trad-
itionally identified with pathological molecular abnor-
malities in AD, retina has recently been documented to
be equivalently involved in the morbidity process [27].
Some specialists point out that the detectable Aβ would
turn up in patients’ retina in the early stages rather than
advanced ones, which provides pre-diagnostic evidence
before the occurrence of dementia [28]. The pertinent
experiment carried out on animals also reaches a similar
conclusion. Over-production of Aβ and β-amyloid pla-
ques in retina were detected prior to behavior trans-
formation and cognitive impairment in AD-transgenic
animals [28,29]. Dependent on aforementioned facts and
data, we selected retina as an experimental object to ex-
plore the effect of Timosaponin-BII on Aβ laid in this
conclusion and relevant evidence about Aβ presence in-
ferred from our previous studies [11,12].
Oxidative stress has long been unequivocally esteemed
as one of the principal etiological factors of AD [30-33].Related reports illustrated that Aβ had an oxidative tox-
icity for neurons [34], while current evidence supports
the amplifying effect of oxidative stress on Aβ aggrega-
tion [7]. Thus, a complete self-enforcing circle including
Aβ accumulation and reactive oxygen production even-
tually resulted in neuronal death. Our previous data
revealed that the FeCl3 induced oxidative stress up-
regulated BACE1 expression [12], compatible with
Tamagno’s conclusion that oxidative stress promoted
BACE1 activation in NT2 cells [15]. In our present
study, the apparent increase of BACE1 protein and
cleavage product Aβ, as well as MDA in FeCl3 treated
retina indicated the success in constructing the oxidative
model.
Timosaponin-BII is widely accepted as neuronal pro-
tective chemicals extracted from Chinese traditional
herb (Anemarrhena asphodeloides). Nevertheless, the
mechanisms of its prevention for neurons from injury
still remain to be further elucidated. Several primary hy-
potheses contribute to this issue. First of all,
Timosaponin-BII may inhibit the inflammation in nerve
system under pathological conditions in the context of
its inhibitory effect on the generation of pro-
inflammatory factors IL-1, IL-6 and TNF [20,21,35]. Sec-
ond, Timosaponin-BII partly restores rats’ intelligence
quality that is suppressed by Aβ aggregation through the
ameliorating activity of acetylcholine esterase (AchE)
[36]. Third, some specialists believe that anti-platelet
and antithrombotic activities of Timosaponin-BII poten-
tially prevent the recurrence of thrombus formation and
preserve cerebral blood flow, contributing its neuropro-
tective effect against cerebral ischemia dementia [24,35].
Although little involvement of Timosaponin-BII in ex-
trinsic coagulation system was observed, Lu’s experiment
evidently demonstrated its inhibition effect on intrinsic
coagulation system. Timosaponin-BII may prevent
against the formation and extension of blot clots, which
consequently preclude cognitive impairment from ische-
mia. Our result was in agreement with Lu’s conclusions,
but whether the anti-platelet effect influence the blood
supply of retina still remains to be investigated. Further-
more, Timosaponin-BII may reduce the direct damage
to neurons with its anti-oxidative property [22]. The
present data showed that the application of
Timosaponin-BII to oxidant injury model led to the de-
crease of BACE1 protein and Aβ, together with the oxi-
dative product (MDA) in vivo. This abatement of
BACE1 production associated with the degraded level of
MDA in Timosaponin-BII treated animals examined by
our group and others. These similar observations may
raise conceptual concern to the underlying neuroprotec-
tive potential of Timosaponin-BII in oxidative-stress-
related aggregation of Aβ in AD pathology. It is tempting
to presume that Timosaponin-BII not only prevents the
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inhibits the process of the “oxidative stress—BACE1—
Aβ—neuronal damage” initially with its anti-oxidative
capacity, finally resulting in a neuroprotective effect.
It is worthwhile to note with regard to the level of
reactive oxygen, BACE1 protein and overproduction of
Aβ still remains higher than those of normal control.
We believe that the mass of acute and intensive im-
pairment in retina induced with immediate oxidant in-
jection elevates the level of BACE1 protein and Aβ in a
short time, while the anti-oxidative capability of
Timosaponin-BII prevents further injury caused by re-
active oxygen species rather than eliminating the pre-
existing pathological molecule, leaving Aβ aggregation
in the tissue unvarnished. Additionally, the discrepancy
could also be attributed to the complexity in the
mechanisms of oxidative stress and the limited compe-
tence of Timosaponin-BII as a single monomer from
nature plants. At present, there are some limitations of
the effects of Timosaponin-BII. However, in terms of
its predominant merit in reducing level of oxidant
stress and inhibiting the up-regulation of BACE1, our
results suggested Timosaponin-BII had the neuropro-
tective potential through interference with molecules
related to Aβ production.
Conclusion
This present study indicated that Timosaponin-BII
inhibited the up-regulation of BACE1 caused by FeCl3 in
rats retina and reduced the production of Aβ presum-
ably with its anti-oxidant potentials.
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